bluuebunny/crossref_metadata_2025_split huggingface dataset:
Abstract 824: Comparison of the high risk HPV detection methods (HC II, DNA Chip, and luminex-based assay) in cervical lesion of Korean women
Authors: Shin Jae Eun , Kim Yun Sun , Kim Ku Hee , Bae Sumi , Kim Yong Wook , Park Dong Chun , Ahn Woong Shick 
Published: February 2011

Abstract
The detection of human papillomavirus (HPV) of female genital tract is very important, several HPV DNA detection methods have been developed during the last decade. In previous report, we introduced luminex-based HPV genotyping assay that is combined PCR amplification. In this study, we compared performances to detect high risk HPV types in hybrid capture 2 (HC II), DNA Chip, and luminex-based assay.
A total of 330 cervical swabs from Cervical Cancer Early Diagnostic Clinic, Seoul St. Mary's Hospital were investigated. DNA was extracted from a single sample and HPV DNA detection assays were performed on the same specimen with 3 strategies and confirmed by DNA sequencing. Among 330 cervical swabs, 230 were HPV positive, 100 were negative.
HPV detection rates of Luminex, HC II and DNA Chip in 330 specimens were 65.2%, 61.2% and 68.8%, respectively. The results of DNA sequence analysis, accuracy of Luminex, HC II and DNA Chip was 91.2%, 82.7% and 80.9%, respectively. HPV DNA infection slightly increase with severity of disease in cytologic and histologic diagnosis, there is no correlation between HPV, because HPV DNAs were detected in many samples with normal in this study.
Conclusively in HPV detection comparison, DNA Chip had relatively high detection rate than Luminex and HC II, but Luminex had the highest accuracy for HPV DNA detection. These results indicate that the Luminex-based assay has more accurate performance than DNA Chip and HC II assay in the detection of HPV infections. We suggest that Luminex-based assay may be useful method for detecting of HPV infection clinically.
Note: This abstract was not presented at the AACR 101st Annual Meeting 2010 because the presenter was unable to attend.
Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 824.
Abstract 828: Progranulin is a good predictive biomarker in ovarian cancer patients followed in first remission
Authors: Han Jasmine J. , Yu Minshu , Hays John L. , Kohn Elise C. 
Published: February 2011

Abstract
Both secretory leukocyte protease inhibitor (SLPI) and progranulin (PGRN) are upregulated and overexpressed in ovarian cancers (OvCa). SLPI has important function in carcinogenesis as a proliferation and survival factor. PGRN is a potent growth and survival factor for cancer cells, and binds to SLPI, the complex of which protects PGRN from degradation by elastase. Recently, human epididymis protein 4 (HE4), located at the same whey acidic protein (WAP) genomic locus as SLPI and with similar structure, has been FDA approved for monitoring OvCa recurrence. We explored the application of SLPI and PGRN as monitoring biomarkers for OvCa recurrence. Archived plasma samples from 23 OvCa patients in first clinical remission, that had been collected prospectively every 3 months until relapse, were used to measure SLPI and PGRN concentrations; archival CA125 results and HE4 measured using commercially available ELISA were controls. Initial PGRN concentration, at study entry, was identified as a predictive factor. Thirteen of 23 patients had elevated PGRN concentrations and normal CA125 at the time of clinical remission. Eleven of those 13 patients recurred within 18 months (p= &lt;0.03), with sensitivity and specificity of 79% and 78%, respectively. HE4 progressively increased in 19 of 23 patients, and 9 patients had positive change &gt;12 months prior to the clinical progression. Only one patient maintained stable HE4 concentration and remains in remission; 3 patients who had stable HE4 concentrations relapsed at 14, 18, and 30 months. Five patients are still in clinical remission, but HE4 concentrations are increased in 4 of 5. In our small panel, HE4 had sensitivity and specificity of 77% and 10%, respectively. For the first time, our work evaluated SLPI and PGRN as predictive and monitoring biomarkers for OvCa recurrence. Additional study is needed to validate the usefulness of PGRN as a predictive factor in OvCa remission.
Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 828.
Abstract 829: A panel of three biomarkers for differentiating high from low grade neuroendocrine tumors of the lung: Findings from a Pilot Project
Authors: Nawaz Nava K. , Lin Fan , Stark Azadeh , Schuerch Conrad 
Published: February 2011

Abstract
Background: Distinguishing low/intermediate grade (carcinoid & atypical carcinoid) from high grade neuroendocrine carcinoma [small cell carcinoma & large cell neuroendocrine carcinoma (LCNEC)] of the lung can be difficult, especially in small biopsy specimens. This distinction is important for appropriate planning of a patient's course of treatment. Expression of biomarkers can be used to improve the precision of a differential diagnosis. We evaluated the expression of a panel of 5 biomarkers: CD117, a cytokine receptor, and KOC, a member of the insulin-like growth factor messenger RNA-binding protein family; Ki-67, a proliferation marker; the von Hippel-Lindau gene product (pVHL) and p16, 2 tumor suppresser markers. This panel was chosen because of their biological functions and their differential expression in low/intermediate vs. high grade cacinomas.
Method: We studied 42 consecutive cases of carcinoma of the lung (20 small cell carcinomas, 7 large cell neuroendocrine carcinomas, 12 carcinoids and 3 atypical carcinoids). Tissue microarrays were constructed and biomarkers’ expressions were evaluated immunohistochemically. Staining was standardized and scored as “0+” = Negative, “1+” = Focal, “2+” = 30-49% cells staining and “3+” = 50-100% cells staining positively. A specimen scored as “0” / “1+” was classified as negative, while a specimen scored as “2+” / “3+” was considered positive. The likelihood of expression of the panel by histopathologic diagnosis was estimated using two-sided non-parametric statistical techniques.
Results: Statistically significant differential expression for KOC, p16, pVHL and Ki-67 between low and high grade tumors was seen, but no significant difference for CD117 was detected. High grade tumors showed greater expression of Ki-67 (OR=13.85, 95% CI 3.34-57.47, p=0.0003), p16 (OR=3.52, 95% CI 1.75-7.11, p=0.0004) and KOC (OR=4.24, 95% CI 1.88-9.56, p=0.0005); while, pVHL expression was lower in high relative to low/intermediate grade tumors (OR=0.31, 95% CI 0.12-0.84, p=.022). We detected a statistically significant probability of the joint over-expression of 3 of the 5 biomarkers [p16 and KOC and Ki-67] in LCNEC relative to atypical carcinoids (OR=2.53, 95% CI 1.24-5.17, p=.011).
Conclusion: Findings suggest that Ki-67, KOC and p16 is an effective antibody panel in differentiating high from low/intermediate grade neuroendocrine carcinoma.
Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 829.
Abstract 83: A role of hepatic retinoid storage in diethynitrosamine-induced hepatic injury and hepatocarcinogenesis
Authors: Shirakami Yohei , Moriwaki Hisataka , Blaner William S. 
Published: February 2011

Abstract
The liver is the main tissue site of retinoid (vitamin A and its derivatives) storage in the body and the non-parenchymal hepatic stellate cell (HSC) is the major cellular site of retinoid storage within the liver. Lipid droplets of HSCs contain a number of bioactive metabolites including retinoids. Following liver injury, HSCs undergo a process known as activation. Loss of retinyl esters, the retinoid storage form, and lipid droplets from HSCs is one of the first events in the development of hepatic disease, leading progressively to liver fibrosis, cirrhosis and hepatocellular carcinoma (HCC). Although the loss of lipid droplets is a hallmark of HSC activation, whether it is a cause or consequence of the HSC activation process is unclear. Moreover, the contribution of the loss of hepatic retinoid storage to hepatic injury and hepatocarcinogenesis remains unknown. To investigate the role of hepatic retinoid storage and retinoid-containing lipid droplets in hepatic injury and hepatocarcingenesis, we studied diethynitrosamine (DEN)-induced HCC in lecithin:retinol acyltransferase (LRAT) knockout (KO) mice, which lack retinoid-containing lipid droplets in their HSCs, and in retinol-binding protein (RBP) KO mice, which are unable to mobilize hepatic retinoid stores. We measured a number of factors implicated in hepatic injury and cancer initiation. Using an acute hepatic injury model for investigating cancer initiation, assessment of mRNA levels by qRT-PCR of TNF alpha and TGF beta in livers of LRAT KO mice indicated that these mice were more susceptible to cancer initiation than WT mice. On the other hand RBP KO mice showed less susceptibility. LRAT KO mice showed higher levels of CYP26A1, a gene whose expression is known to be highly and directly responsive to retinoic acid level, suggesting that hepatic retinoic acid levels in LRAT KO mice were higher than that of WT, and that this may influence hepatic injury and carcinogenesis. Overall, our data suggest that hepatic retinoid storage can influence the progression of hepatic disease.
Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 83.
Abstract 831: uPAR Expression is Up-regulated in Cervical Cancer
Authors: Sasaki Toru , Nishi Hirotaka , Terauchi Fumitoshi , Higuma Chinatsu , Nagai Takeshi , Nagao Toshitaka , Isaka Keiichi 
Published: February 2011

Abstract
Hypoxia occurs during development of cervical cancer and is considered to correlate with its invasion. Hypoxia induces cancer cells to have more invasive property through the urokinase plasminogen activator receptor (uPAR) expression. Also, poor prognosis of uterine cervical cancer is correlated with hypoxic condition. Thus, we examined the relationship among the uPAR mRNA level and clinical prognostic factors, such as clinical and pathological stage, hemoglobin level, histologic type, tumor marker level and the effect on clinical outcome, using 66 cases of cervical cancer and 10 normal cervical tissues. These factors were evaluated by t test and Spearman's rank correlation coefficient. Survival analysis was performed using Kaplan-Meier curves. The uPAR mRNA level is significantly up-regulated in cervical cancers, compared with that in normal cervixes. The level of hemoglobin was significantly correlated with uPAR mRNA expression. Whereas, no other clinical prognostic factor had correlation with uPAR mRNA expression. Also, the uPAR mRNA level was not correlated with survival. According to the invasion assays, cervical cancer cell lines, CA and CaSki, under hypoxic condition (1% O2) showed more invasive property than those under normoxia. Hypoxia enhanced the endogenous uPAR mRNA level and protein expression by realtime RT-PCR and western blot analysis, respectively. Although we hypothesized that uPAR expression was correlated with tumor invasion and poor prognosis, the results revealed that uPAR mRNA expression was not correlated with survival nor most clinical factors except for the hemoglobin level. Although uPAR seems to be critical for the invasiveness in cervical cancer cell lines, uPAR may not be involved in cervical cancer invasion in vivo. Only real hypoxia may regulate the uPAR mRNA expression in cervical cancer.
Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 831.
Abstract 839: HER2 expression occurs early in breast cancer dissemination
Authors: Ignatiadis Michail , Durbecq Virginie , Veys Isabelle , Rosari Jose , Criscitiello Carmen , Bedard Philippe , Singhal Sandeep K. , Buxant Frédéric , Chaboteaux Carole , Ghizlane Rouas , Larsimont Denis , Liebens Fabienne , Piccart Martine , Sotiriou Christos 
Published: February 2011

Abstract
Background: Systemic spread of disseminated tumor cells from the primary site may occur early in breast tumorigenesis. The role of HER2 in breast cancer (BC) dissemination is not well understood. We evaluated the expression of HER2 on peripheral blood Circulating Tumor Cells (CTCs) from women with various stages of breast cancer (BC).
Methods: 81 women with preinvasive breast lesions (Atypical Ductal Hyperplasia, Lobular Carcinoma In Situ and Ductal Carcinoma In Situ), 101 women with early invasive BC and 35 women with metastatic BC were included. CTCs were defined as Cytokeratin 8,18,19+/CD45-/DAPI+ cells detected using the CellSearch® technology. Any staining for HER2 on CTCs using the CellSearch® HER2 profiling kit was considered positive. HER2 detection was calibrated through peripheral blood spiking experiments with MCF7 and SKBR3 cells.
Results: &gt; 1 CTCs/22.5mL of blood were detected in 6 of 81 (7%) women with preinvasive breast lesions (range 0-3 CTCs) and 15 of 101 (15%) women with early invasive BC (range 0-8 CTCs), whereas &gt; 1 CTCs/7.5mL of blood were detected in 17 of 35 (49%) women with metastatic BC (range 0-1160 CTCs) (p&lt;0.001). HER2 expression on CTCs was not associated with estrogen receptor (ER) and progesterone receptor (PR) expression or the histological grade of the primary tumor. In women with detectable CTCs, the ratio of HER2-positive CTCs/total CTCs was higher in HER2-positive than HER2-negative primary tumors (p=0.023). Despite a higher detection rate of CTCs, the ratio of HER2-positive CTCs/total CTCs was lower in metastatic BC (median 0.15, range 0-1.0) than in preinvasive (median 1.0, range 0-1.0) or early invasive BC (median 1.0, range 0.3-1.0) (p&lt;0.001). Similar results were observed when only HER2-negative primary tumors were considered (p=0.004).
Conclusion: This is the first report showing that HER2-positive CTCs can be detected in women with preinvasive breast lesions, further supporting the hypothesis that dissemination occurs early in breast tumorigenesis. HER2 expression on CTCs is more commonly observed in earlier stages of breast cancer, suggesting that HER2 plays an important role in early dissemination. The EORTC 90091-10093 trial will test the hypothesis that trastuzumab can eliminate HER2-positive CTCs in patients with HER2-negative early breast cancer.
Note: This abstract was not presented at the AACR 101st Annual Meeting 2010 because the presenter was unable to attend.
Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 839.
Abstract 843: Fast molecular response of marrow disease is highly prognostic in stage 4 neuroblastoma &gt; 1 year
Authors: Stutterheim Janine , Zappeij-Kannegieter Lily , Versteeg Rogier , van der Schoot C. Ellen , Caron Huib N. , Tytgat Godelieve A.M. 
Published: February 2011

Abstract
Aim
Real-time quantitative (RQ)-PCR for detection of minimal residual disease (MRD) in children with neuroblastoma (NBL) can be used for evaluation of molecular bone marrow (BM) response. However its prognostic value still has to be established. We previously developed a panel of specific neuroblastoma RQ-PCR markers for MRD testing. The goal of this study was to determine whether sequential molecular assessment of BM using this panel of markers was prognostic for overall survival (OS).
Methods
In this single center study, RQ-PCR was performed with five NBL-specific markers: homeobox2b (PHOX2B), tyrosine hydroxylase (TH), dopamine decarbohydroxylase (DDC), growth associated protein 43 (GAP43) and cholinergic receptor3 (CHRNA3), on 106 retrospectively collected samples of 53 patients age &gt; 1 year with metastatic disease. The prognostic impact of MRD at diagnosis (n=39), at 3 months after diagnosis (n=38) and after completing induction chemotherapy (n=29) was assessed using univariate and multivariate Cox regression analysis.
Results
At diagnosis, there was no correlation between tumor load in BM and outcome (Spearman's test, p=0.93). At 3 months after diagnosis, 29%(11/38) of the patients were in molecular BM remission, which was associated with favourable outcome (5-y-OS 62.3±15.0% versus 18.5±7.5%;p=0.009). After completion of induction chemotherapy, BM of 41%(12/29) of the patients was still MRD positive, which was associated with poor outcome (5-y-OS 0% versus 52.3±12,3;p&lt;0.001). For both time points, the prognostic value of molecular response was an independent prognostic factor.
Conclusion
MRD detection measured by a panel of NBL specific-PCR targets could identify fast responders, who clear their BM early during treatment. Fast molecular response was an independent prognostic factor, associated with better outcome.
Note: This abstract was not presented at the AACR 101st Annual Meeting 2010 because the presenter was unable to attend.
Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 843.
Abstract 847: LINE-1 hypomethylation is a marker of poor prognosis in stage IA non-small cell lung cancer
Authors: Saito Kenichiro , Kawakami Kazuyuki , Matsumoto Isao , Oda Makoto , Watanabe Go , Minamoto Toshinari 
Published: February 2011

Abstract
Introduction: Non-small cell lung cancer (NSCLC) has a relatively poor prognosis and is a leading cause of cancer death worldwide. A substantial proportion of NSCLC patients suffer a recurrence following curative tumor resection, even when they have early stage disease. Molecular markers that are able to predict patient prognosis after surgery are therefore of clinical relevance, especially for early stage NSCLC. Global hypomethylation and the hypermethylation of gene promoter regions are common events in tumor DNA and are possible markers to predict clinical course of NSCLC patients. The aim of this study was to evaluate the prognostic significance of both global hypomethylation and gene promoter hypermethylation in DNA from NSCLC.
Methods: Genomic DNA was obtained from tumor tissue of 379 NSCLC patients who underwent surgery. Methylation levels were measured by real-time PCR following bisulfite modification of DNA and were correlated with clinicopathological parameters and patient prognosis. Methylation of long interspersed nuclear element 1 (LINE-1) was used as a surrogate marker for global methylation. Hypermethylation of the APC, CDH13 and RASSF1 promoter regions was also evaluated.
Results: Tumor tissue showed significantly higher CDH13 and RASSF1 methylation levels compared to normal lung tissue, but lower LINE-1 methylation levels. APC, RASSF1 and LINE-1 methylation levels were significant prognostic factors in univariate analysis of an initial cohort of 234 cases. APC and LINE-1 methylation remained significant prognostic factors in multivariate analysis that included age, gender, smoking history, histological type and pathological stage. LINE-1 methylation showed marginally significant prognostic value in stage IA and IB disease. To examine whether LINE-1 methylation was an independent prognostic factor, the study cohort was expanded to 364 cases. In sub-group analysis of stage IA cases with expanded cohort, survival was significantly worse for patients with LINE-1 hypomethylation. Multivariate analysis also revealed that LINE-1 methylation had significant prognostic value for stage IA NSCLC patients. Sub-group analysis failed to show prognostic value for LINE-1 methylation in all other NSCLC disease stages.
Conclusion: LINE-1 hypomethylation was an independent marker of poor prognosis in stage IA NSCLC. Validation of this finding in additional tumor cohorts could have clinical relevance for the management of early stage NSCLC.
Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 847.
Abstract 848: VCAM-1 expression in epithelial ovarian cancer
Authors: Scalici Jennifer M. , Henretta Melissa , Slack-Davis Jill , Atkins Kristen 
Published: February 2011

Abstract
Vascular cell adhesion molecule-1 (VCAM-1) is a cell surface adhesion molecule with known expression on the peritoneum of some advanced stage epithelial ovarian cancer patients. Previous study by our group has implicated VCAM-1 as a mediator of metastatic invasion of peritoneal surfaces by tumor cells in advanced disease, as inhibition of its function resulted in decreased tumor burden and improved overall survival in an animal model. We propose that VCAM-1 expression is a potential site of targeted therapy and in addition, expression may also serve as an early indicator of disease recurrence. We aim to correlate VCAM-1 expression with disease stage and histology to determine when in the course of disease expression begins. After IRB approval, archived tissue blocks from 1998-2008 containing samples of tumor, omentum, and peritoneum were evaluated for the presence of mesothelial cells. IHC staining of VCAM-1 was performed. Samples were evaluated and scored by a single pathologist blinded to stage and tumor type. All tissue samples from stage 1 patients were negative for VCAM-1 expression. The majority of samples from stages 3 and 4 were positive. Of the stage 2 samples, 50% were positive; those were primarily of serous histology. This suggests that there is an increase in peritoneal VCAM-1 expression as tumor cells leave the confines of the ovary and may serve as a marker of metastasis.
Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 848.